Aberrant angiogenesis and dysregulated epigenetic transcription are hallmarks of cancer that mutually reinforce tumor progression and therapeutic resistance. Vascular endothelial growth factor receptor-2 (VEGFR-2) is the principal driver of tumor angiogenesis, while bromodomain-containing protein 4 (BRD4) acts as a master transcriptional coactivator of oncogenes. Herein, we report the design, synthesis, and biological evaluation of a series of novel VEGFR-2/BRD4 dual-targeted inhibitors via a pharmacophore hybridization strategy that merges the aryl urea scaffold of sorafenib with the tetrahydropteridinone core of BI-2536. Among the 43 synthesized compounds, 15h emerged as the most potent dual inhibitor. In cellular assays, 15h demonstrated broad-spectrum antiproliferative activity against Colo829, D121, NCI-H446, and MCF-7 cell lines. Notably, 15h substantially outperformed the physical combination of sorafenib plus (+)-JQ-1, achieving 13.7-fold and 9.8-fold greater potency in D121 and NCI-H446 cells, respectively, thereby validating the superiority of a single-molecule dual-targeting strategy over combination therapy. Kinase selectivity profiling revealed that 15h maintains a favorable selectivity window, with VEGFR-2 being the most potently inhibited target. Importantly, in an NCI-H446 xenograft mouse model, 15h administered at 1.5 mg/kg (i.p.) achieved a tumor growth inhibition (TGI) rate of 109.6%, significantly outperforming sorafenib (TGI = 58.9%) and (+)-JQ-1 (TGI = 53.4%), without significant body weight loss during the treatment period. Collectively, these findings establish 15h as a promising VEGFR-2/BRD4 dual-targeted lead compound and validate the molecular hybridization strategy as an effective approach for developing next-generation antitumor agents that overcome the limitations of physical combination regimens.